

**FLEURY S.A.**  
**Publicly-held Corporation**  
**CNPJ (Tax ID) 60.840.055/0001-31**  
**NIRE 35.300.197.534**

**MATERIAL FACT – SAHA ACQUISITION**

Fleury S.A. ("Company") hereby informs its shareholders and the market in general that, on this date, through its wholly owned subsidiary CIP - Centro de Infusões Pacaembu Ltda ("CIP"), it entered into an Agreement for the Purchase and Sale of Quotas to acquire 100% of the quotas representing the capital stock of Saha Centro de Infusões Ltda. and Saha Serviços Médicos e Hospitalares Ltda. (jointly referred to as the "Companies").

The Companies are renowned immunobiological infusion therapy and medical care centers located in the Metropolitan Region of the City of São Paulo and their gross revenue reached BRL 156.2 million in 2021.

Aligned with the Company's strategy to expand its healthcare ecosystem, this acquisition reinforces the presence in (i) infusion therapy and (ii) lower complexity procedures in ambulatory surgical center (day hospital), a segment that provides greater safety, comfort and cost effectiveness for patients, as well as for paying sources.

On the closing date, the Company will pay the amount of BRL 120.0 million for the acquisition of the Companies.

The conclusion of this transaction is subject to certain conditions precedent, among which, the approval of the acquisition by CADE.

The Company will keep its shareholders and the market informed about the facts related to this transaction.

São Paulo, May 05, 2022.

**JOSÉ ANTONIO DE ALMEIDA FILIPPO**  
Chief Financial and Investor Relations Officer